Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia.
Hernández-Boluda JC, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Martínez-López J, Velez P, Pérez-Encinas M, Estrada N, García-Gutiérrez V, Fox ML, Luño E, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares M, Mata-Vázquez MI, Regadera A, Pereira A, Cervantes F; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Hernández-Boluda JC, et al. Br J Haematol. 2018 May;181(3):397-400. doi: 10.1111/bjh.14601. Epub 2017 Apr 17. Br J Haematol. 2018. PMID: 28419426 Free article. No abstract available.
Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation.
Cervantes F, Hernández-Boluda JC, Odriozola J, Camós M, Villalón L, Martínez-Climent JA, del Campo R, García-Conde J, Montserrat E. Cervantes F, et al. Br J Haematol. 2003 Feb;120(3):500-4. doi: 10.1046/j.1365-2141.2003.04077.x. Br J Haematol. 2003. PMID: 12580969 Free article. Clinical Trial.
Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
Cervantes F, Hernández-Boluda JC, Steegmann JL, Conde E, Alvarez-Larrán A, López-Jiménez J, Osorio S, Villalón L, Camós M, García-Conde J, Odriozola J. Cervantes F, et al. Haematologica. 2003 Oct;88(10):1117-22. Haematologica. 2003. PMID: 14555307 Clinical Trial.
Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia.
Cervantes F, Alvarez-Larrán A, Hernández-Boluda JC, Sureda A, Granell M, Vallansot R, Besses C, Montserrat E. Cervantes F, et al. Br J Haematol. 2006 Jul;134(2):184-6. doi: 10.1111/j.1365-2141.2006.06142.x. Epub 2006 Jun 1. Br J Haematol. 2006. PMID: 16740139 Free article. Clinical Trial.
Prognostic factors in chronic myeloid leukaemia.
Hernández-Boluda JC, Cervantes F. Hernández-Boluda JC, et al. Best Pract Res Clin Haematol. 2009 Sep;22(3):343-53. doi: 10.1016/j.beha.2009.04.005. Best Pract Res Clin Haematol. 2009. PMID: 19959085 Review.
221 results